Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study (Q35592257)

9 August 2017

title

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study (English)

1 reference

9 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

35

Anthony S Fauci

1 reference

9 August 2017

Amy Nelson

4

0 references

David E. Kleiner

object named as

David E Kleiner

26

0 references

Shyam Kottilil

37

object named as

Shyam Kottilil

1 reference

9 August 2017

23

Gebeyehu Teferi

1 reference

9 August 2017

2

Anuoluwapo Osinusi

1 reference

9 August 2017

13

Sreetha Sidharthan

1 reference

9 August 2017

11

Chloe Gross

1 reference

9 August 2017

20

Michael Proschan

1 reference

9 August 2017

3

Zayani Sims

1 reference

9 August 2017

32

Phillip S Pang

1 reference

9 August 2017

7

Dimitra Bon

1 reference

9 August 2017

10

Colleen Kotb

1 reference

9 August 2017

8

Miriam M Marti

1 reference

9 August 2017

9

Rachel Silk

1 reference

9 August 2017

36

Henry Masur

1 reference

9 August 2017

24

Rohit Talwani

1 reference

9 August 2017

Anita Kohli

1

1 reference

9 August 2017

Eric G Meissner

5

1 reference

9 August 2017

Lisa L Barrett

6

1 reference

9 August 2017

Tim A Jolley

12

1 reference

9 August 2017

Tess Petersen

14

1 reference

9 August 2017

Kerry Townsend

15

1 reference

9 August 2017

D'Andrea Egerson

16

1 reference

9 August 2017

Rama Kapoor

17

1 reference

9 August 2017

Emily Spurlin

18

1 reference

9 August 2017

Michael Sneller

19

1 reference

9 August 2017

Eva Herrmann

21

1 reference

9 August 2017

Richard Kwan

22

1 reference

9 August 2017

Gabbie Diaz

25

1 reference

9 August 2017

Brad J Wood

27

1 reference

9 August 2017

Jose Chavez

28

1 reference

9 August 2017

Stephen Abbott

29

1 reference

9 August 2017

William T Symonds

30

1 reference

9 August 2017

G Mani Subramanian

31

1 reference

9 August 2017

John McHutchison

33

1 reference

9 August 2017

Michael A Polis

34

1 reference

9 August 2017

language of work or name

English

0 references

publication date

13 January 2015

1 reference

9 August 2017

1 reference

9 August 2017

volume

385

1 reference

9 August 2017

issue

9973

1 reference

9 August 2017

page(s)

1107-1113

1 reference

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Faldaprevir and deleobuvir for HCV genotype 1 infection.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Sofosbuvir for previously untreated chronic hepatitis C infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Preliminary study of two antiviral agents for hepatitis C genotype 1.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Response-guided telaprevir combination treatment for hepatitis C virus infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Exploratory study of oral combination antiviral therapy for hepatitis C.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4427052

10.1016/S0140-6736(14)61228-9

26 September 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference

9 August 2017

1 reference